Search / Trial NCT00001060

A Phase I Trial of HIV-1 C4-V3 Polyvalent Peptide Vaccine in HIV-1 Infected Persons

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Apply for Trial

Trial Information

Current as of May 23, 2024

Completed

Keywords

Vaccines, Synthetic Hiv 1 Acquired Immunodeficiency Syndrome Aids Related Complex Aids Vaccines Hiv Therapeutic Vaccine

Description

HIV-1 C4-V3 polyvalent peptide vaccine contains amino acid sequences for selected epitopes from four of the most common HIV isolates in the United States and Europe, predicted to represent about 50-90 percent of the HIV isolates in the United States. It includes epitopes that generate potentially salutary immune responses and deletes epitopes that generate immune responses which might contribute to further immunopathogenesis. Patients are randomized to receive low-dose or high-dose HIV-1 C4-V3 polyvalent peptide vaccine in incomplete Freund's adjuvant (IFA), or IFA alone as control. Inject...

Gender

All

Eligibility criteria

  • Inclusion Criteria
  • Concurrent Medication:
  • Allowed:
  • Other medically indicated vaccinations, provided they are administered at least 2 weeks before or after any study injection.
  • Alcohol use limited to 1 oz per day of 100 proof.
  • Patients must have:
  • HIV infection without evidence of AIDS.
  • CD4 count > 500 cells/mm3.
  • Exclusion Criteria
  • Co-existing Condition:
  • Patients with the following symptoms or conditions are excluded:
  • Current evidence of underlying lung or liver disease.
  • Suspected or diagnosed allergy to any vaccine component.
  • Medical contraindication to protocol participation.
  • Undergoing allergy skin testing or desensitization.
  • Concurrent Medication:
  • Excluded:
  • Antiretroviral therapy (unless clinically indicated and with approval of investigator).
  • Immunosuppressive or immunomodulatory therapy.
  • Nonsteroidal anti-inflammatory agents (except short-term therapy for acute conditions).
  • Drugs with known hepatotoxicity.
  • Alcohol intake > 1 oz per day of 100 proof.
  • Patients with the following prior conditions are excluded:
  • History of underlying lung disease.
  • Abnormal chest radiograph within 2 weeks prior to first vaccine injection.
  • History of underlying liver disease.
  • Abnormal hepatitis B surface antigen or hepatitis C antibody test within 2 weeks prior to first vaccine injection.
  • Abnormal liver function tests within 30 days prior to study entry.
  • Evidence of uveitis by slit lamp exam within 2 weeks prior to study entry.
  • Anergic as evidenced by negative skin test responses to all three antigens in a panel consisting of tetanus toxoid, mumps, and Candida albicans, within 6 weeks prior to first vaccine injection.
  • Prior participation on an HIV vaccine trial.
  • Prior Medication:
  • Excluded within the past 3 months:
  • Antiretroviral therapy.
  • Immunosuppressive drugs.
  • Alpha interferon or any immunomodulatory drugs.
  • Any investigational HIV drugs or therapies. Current alcohol abuse.

Attachments

readout_NCT00001060_2024-05-23.pdf

4.5 MB

NCT00001060_study_protocol.pdf

4.5 MB

About company

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Durham, North Carolina, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Reviews (48)

4.6

All reviews come from applied patients

5 stars
41
4 stars
6
3 stars
2
2 stars
0
1 stars
0
Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Michael Foster
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Dries Vincent
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Leslie Alexander
20 September 2023

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum?

Discussion 0